CORCEPT THERAPEUTICS INC
CORTReported to SECin USCIK 0001088856Filings at SEC EDGAR
No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.
This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 120. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
The most recent filings
Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.
| Filed by | Type | Value | Reported | Filed by | Value | Type | Shares | Reported |
|---|---|---|---|---|---|---|---|---|
| Robb Gary CharlesChief Business Officer | Gift | nothing paid5,000 shares | Sep 28, 2026 | Robb Gary CharlesChief Business Officer | nothing paid | Gift | 5,000 | Sep 28, 2026 |
| Robb Gary CharlesChief Business Officer | Gift | nothing paid5,000 shares | Sep 28, 2026 | Robb Gary CharlesChief Business Officer | nothing paid | Gift | 5,000 | Sep 28, 2026 |
| Robb Gary CharlesChief Business Officer | Gift | nothing paid17,100 shares | Sep 28, 2026 | Robb Gary CharlesChief Business Officer | nothing paid | Gift | 17,100 | Sep 28, 2026 |
| Vieira Roberto WandenkolkPresident, Oncology | Open-market sell | $29,843296 shares | Sep 18, 2026 | Vieira Roberto WandenkolkPresident, Oncology | $29,843 | Open-market sell | 296 | Sep 18, 2026 |
| Robb Gary CharlesChief Business Officer | Option exercise | nothing paid17,493 shares | Sep 18, 2026 | Robb Gary CharlesChief Business Officer | nothing paid | Option exercise | 17,493 | Sep 18, 2026 |